drugset / Trial / NCT05376722
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
Phase 2
Unknown
30 enrolled
Hongqian Guo
First Affiliated Hospital of Zhejiang University · collabNanjing First Hospital, Nanjing Medical University · collabThe First Affiliated Hospital of Soochow University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy
Timeline
- Start
- 2022-02-22
- Primary completion
- 2023-09
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Pamiparib | Small molecule | 40 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |
Indications
No indication recorded.